Rolf‐Markus Szeimies
Research Subjects
Rolf‐Markus Szeimies has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
M. Landthaler
Department of Dermatology
3 shared publicationsC. Abels
Department of Dermatology, University of Regensburg, Franz‐Josef‐Strauss‐Allee 11, 93042 Regensburg, Germany
1 shared publicationC. Gottschaller
Department of Dermatology
1 shared publicationE-M. Reisberger
Department of Dermatology, University of Regensburg, Franz-Josef-Strauss-Allee 11, 93042 Regensburg, Germany
1 shared publicationHeidi Bäcker
Klinik und Poliklinik für Dermatologie Klinikum der Universität Regensburg
1 shared publicationK.E. Douwes
Department of Dermatology, University of Regensburg, D-93042 Regensburg, Germany
1 shared publication
Latest Publications
- 1 July 2007
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 157 (1) , 111-117
Variable pulsed light is less painful than light-emitting diodes for topical photodynamic therapy of actinic keratosis: a prospective randomized controlled trial
Photodynamic therapy (PDT) of actinic keratosis (AK) using methylaminolaevulinate (MAL) is an effective and safe treatment option, but the procedure is painful. To evaluate the efficacy and pain associated with variable pulsed light (VPL), a prospective, randomized, controlled split-face study was performed. Topical MAL-PDT was conducted in 25 patients with AK (n = 238) who were suitable for two-sided comparison. After incubation with MAL, irradiation was performed with a light-emitting diode (LED) (50 mW cm(-2); 37 J cm(-2)) vs. VPL (80 J cm(-2), double pulsed at 40 J cm(-2), pulse train of 15 impulses each with a duration of 5 ms, 610-950 nm filtered hand piece) followed by re-evaluation up to 3 months. The pain during and after therapy was significantly lower with VPL irradiation [t (d.f. = 24) = 4.42, P < 0.001]. The overall mean +/- SD infiltration and keratosis score at 3 months after treatment was 0.86 +/- 0.71 (LED system) vs. 1.05 +/- 0.74 (VPL device) (no statistically significant difference; P = 0.292). Patient satisfaction following both treatment modalities did not significantly differ at the 3-month follow up (P = 0.425). VPL used for MAL-PDT is an efficient alternative for the treatment of AK that results in complete remission and cosmesis equivalent to LED irradiation but causes significantly less pain.
- 1 July 2007
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 157 (1) , 111-117
Variable pulsed light is less painful than light-emitting diodes for topical photodynamic therapy of actinic keratosis: a prospective randomized controlled trial
Photodynamic therapy (PDT) of actinic keratosis (AK) using methylaminolaevulinate (MAL) is an effective and safe treatment option, but the procedure is painful. To evaluate the efficacy and pain associated with variable pulsed light (VPL), a prospective, randomized, controlled split-face study was performed. Topical MAL-PDT was conducted in 25 patients with AK (n = 238) who were suitable for two-sided comparison. After incubation with MAL, irradiation was performed with a light-emitting diode (LED) (50 mW cm(-2); 37 J cm(-2)) vs. VPL (80 J cm(-2), double pulsed at 40 J cm(-2), pulse train of 15 impulses each with a duration of 5 ms, 610-950 nm filtered hand piece) followed by re-evaluation up to 3 months. The pain during and after therapy was significantly lower with VPL irradiation [t (d.f. = 24) = 4.42, P < 0.001]. The overall mean +/- SD infiltration and keratosis score at 3 months after treatment was 0.86 +/- 0.71 (LED system) vs. 1.05 +/- 0.74 (VPL device) (no statistically significant difference; P = 0.292). Patient satisfaction following both treatment modalities did not significantly differ at the 3-month follow up (P = 0.425). VPL used for MAL-PDT is an efficient alternative for the treatment of AK that results in complete remission and cosmesis equivalent to LED irradiation but causes significantly less pain.
- 16 March 2005
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 3 (4) , 284-299
Die Therapiestrategien bei kutaner Sarkoidose
- 16 March 2005
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 3 (4) , 284-299
Die Therapiestrategien bei kutaner Sarkoidose
- 10 December 2004
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 19 (1) , 1-20
Novel pharmacological approaches in the treatment of psoriasis
Progress in the understanding of psoriasis as a T‐cell mediated inflammatory disease has led to the development of new immunomodulatory therapies. Currently the main focus is on the so‐called biologics (or biological agents), including fusion proteins, monoclonal antibodies, cytokines and selective receptors. They mainly target single steps in the complex cascade of humoral and cellular inflammatory immunomechanisms that finally lead to the accelerated growth of epidermal and vascular cells in the psoriatic lesions. The most promising and advanced biological agents are discussed along with their influence on the critical pathophysiological steps in psoriasis, including depletion of T cells, blockade of initial T‐cell activation and T‐cell receptor (TCR) stimulation, blockade of costimulatory signals and T‐cell proliferative signals as well as restoration of the T helper type 1 (Th1)/Th2 balance by diminishing type 1 cytokines and administration of type 2 cytokines. In addition to the biological agents, further development of ‘classical’ dermatological therapies, such as retinoids, or the discovery of new indications for non‐dermatological agents contribute to the novel pharmacological approaches in the treatment of psoriasis.
- 10 December 2004
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 19 (1) , 1-20
Novel pharmacological approaches in the treatment of psoriasis
Progress in the understanding of psoriasis as a T‐cell mediated inflammatory disease has led to the development of new immunomodulatory therapies. Currently the main focus is on the so‐called biologics (or biological agents), including fusion proteins, monoclonal antibodies, cytokines and selective receptors. They mainly target single steps in the complex cascade of humoral and cellular inflammatory immunomechanisms that finally lead to the accelerated growth of epidermal and vascular cells in the psoriatic lesions. The most promising and advanced biological agents are discussed along with their influence on the critical pathophysiological steps in psoriasis, including depletion of T cells, blockade of initial T‐cell activation and T‐cell receptor (TCR) stimulation, blockade of costimulatory signals and T‐cell proliferative signals as well as restoration of the T helper type 1 (Th1)/Th2 balance by diminishing type 1 cytokines and administration of type 2 cytokines. In addition to the biological agents, further development of ‘classical’ dermatological therapies, such as retinoids, or the discovery of new indications for non‐dermatological agents contribute to the novel pharmacological approaches in the treatment of psoriasis.
- 1 April 2003
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 148 (4) , 749-754
Histopathological diagnosis of onychomycosis by periodic acid-Schiff-stained nail clippings
Summary Background The current laboratory methods for diagnosing fungal infections of the nails are the potassium hydroxide (KOH) scraping technique and fungal culture. However, due to the long incu...
- 1 April 2003
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 148 (4) , 749-754
Histopathological diagnosis of onychomycosis by periodic acid-Schiff-stained nail clippings
Summary Background The current laboratory methods for diagnosing fungal infections of the nails are the potassium hydroxide (KOH) scraping technique and fungal culture. However, due to the long incu...
- 1 July 2000
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 143 (1) , 195-197
Simultaneous occurrence of folliculitis decalvans capillitii in identical twins
Folliculitis decalvans is a chronic purulent folliculitis resulting in permanent hair loss and follicular atrophy. We report 32‐year‐old identical female twins presenting with relapsing pruritic outb...
- 1 July 2000
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 143 (1) , 195-197
Simultaneous occurrence of folliculitis decalvans capillitii in identical twins
Folliculitis decalvans is a chronic purulent folliculitis resulting in permanent hair loss and follicular atrophy. We report 32‐year‐old identical female twins presenting with relapsing pruritic outb...